Depomed (DEPO)

[surf1944]

8:02AM DepoMed reports that BREEZE 3 data for Serada was presented that showed that may help manage menopausal hot flashes (DEPO) 6.14 : The results of the supportive ANCOVA parametric analysis of the BREEZE 3 data were presented at NAMS. In this analysis, Serada significantly reduced the frequency and severity of hot flashes at 4 weeks and 12 weeks compared with placebo. These reductions were maintained out to 24 weeks. In addition, an assessment of sleep measures taken at the start of the trial indicated that, on average, women had clinically meaningful improvements in insomnia and sleep disturbance.